Stock report · Delisted · Nasdaq
Carmell Therapeutics Corporation (CTCX)
0.20USD Delisted Final close · Mar 7, 2025
CTCX no longer trades. Carmell Therapeutics was delisted from the Nasdaq in March 2025.
All prices on this page are historical. The last trade was on March 7, 2025, at $0.20.
CTCX stock price history
Final trading statistics
- Final close
- $0.20
- Final trading day
- Mar 7, 2025
- Market cap at delisting
- $5.94M
- Shares outstanding
- 30.12M
- Final 52-week range
- $0.17 – $3.05
- Avg. volume (final 3 mo.)
- 6,917,576
- All-time high
- $11.00 · Jul 2023
- All-time low
- $0.19 · Mar 2025
- Return since IPO
- -98.0%
- Beta
- 0.51
- Book value / share
- −$0.19
- Price / book
- -1.02
About Carmell Therapeutics Corporation
Carmell Corporation, formerly Carmell Therapeutics, was a bio-aesthetics company focused on skin and hair health. Its Carmell Secretome was made of growth factors and proteins taken from donated human platelets sourced from tissue banks.
It also created a microemulsion formula that delivers oil- and water-soluble ingredients without the Foul Fourteen, a group of 14 possibly harmful excipients often used in cosmetics. The company was working on a men's line and topical haircare products, and it held a license from Carnegie Mellon University to develop plasma-based biocompatible plastics.
It took the Carmell Corporation name in November 2023. Founded in 2008, it was based in Pittsburgh, Pennsylvania. Its stock was delisted from the Nasdaq in March 2025, with the last trade on March 7, 2025 at $0.20.
- Exchange (former)
- Nasdaq
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Headquarters
- Pittsburgh, PA
- Employees
- 9
- IPO date
- July 17, 2023
- Delisted
- March 7, 2025
- SEC CIK
- 1842939
Carmell Therapeutics financials before the delisting
The last 4 fiscal years Carmell Therapeutics reported as a public company, fiscal year ending December.
CTCX revenue and net income
CTCX earnings per share
CTCX annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $50.3K | −$10.4M | — |
| FY2023 | $0.00 | −$15.4M | — |
| FY2022 | $0.00 | −$9.1M | $0.02 |
| FY2021 | $0.00 | −$6.5M | −$0.02 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Carmell Therapeutics stock FAQ
What happened to Carmell Therapeutics stock?
Carmell Therapeutics was delisted from the Nasdaq in March 2025. The final close was $0.20 on March 7, 2025.
Can I still buy CTCX stock?
No. CTCX is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on March 7, 2025.
What was the last price of CTCX?
CTCX last closed at $0.20 on March 7, 2025, which valued the company at about $5.94M.
How did Carmell Therapeutics do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Carmell Therapeutics reported revenue of $50.3K and net income of −$10.4M.
When did Carmell Therapeutics go public?
Carmell Therapeutics shares started trading on July 17, 2023.
CTCX no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.